BioPharma APAC: R‑biolin matches Novolin® R in pre‑clinical tests, gears up for 50× scale‑up and human trials
Why this story matters
BioPharma APAC reports that rBIO’s lead biosimilar insulin candidate, R‑biolin, achieved bioequivalence to Novo Nordisk’s Novolin® R in animal studies—an important validation step that clears the path for a 50‑fold manufacturing scale‑up and the first‑in‑human trials planned for later this year.
“R‑biolin matched Novolin® R in preclinical studies, validating its potential as a cost‑effective biosimilar insulin.” — BioPharma APAC
See how rBIO is transforming insulin affordability and access.
